Clinical Trials Directory

Trials / Unknown

UnknownNCT04763057

Indirect Pulp Treatment in Primary Teeth

Calcium Hydroxide Versus NeoPUTTY MTA in Indirect Pulp Treatment of Primary Molars: A Randomized Clinical Trial

Status
Unknown
Phase
N/A
Study type
Interventional
Enrollment
88 (estimated)
Sponsor
Cairo University · Academic / Other
Sex
All
Age
4 Years – 8 Years
Healthy volunteers
Not accepted

Summary

Conservative approaches such as indirect pulp capping techniques became popular over the last years for the management of deep carious lesions. In particular, indirect pulp-treatment (IPT) techniques have gained remarkable attention in pediatric dentistry, mainly because children require a fast and accurate treatment, besides it enables the affected primary tooth to remain in the mouth until exfoliation without causing any pain or infection.

Detailed description

Indirect pulp treatment is recommended for teeth with deep caries approximating the pulp with no signs and symptoms of pulp deterioration. In this treatment, the deepest layer of the remaining carious dentine (affected dentin) is covered with biocompatible material followed by an airtight restoration to achieve a good seal against microleakage, without the need to reencounter for the removal of remaining caries. Calcium hydroxide has served as a gold standard for IPT over the years. However, the introduction of newer bioactive materials such as mineral trioxide aggregate (MTA) and Biodentine helped surpass the demerits of calcium hydroxide such as internal resorption, nonadherence to dentin, degradation over time, tunnel defects, and poor sealing ability.

Conditions

Interventions

TypeNameDescription
DRUGNeoPUTTY MTANeoPUTTY, a premixed bioactive bioceramic MTA that triggers hydroxyapatite and supports healing
DRUGcalcium hydroxideCalcium hydroxide the gold standard for IPT

Timeline

Start date
2021-04-01
Primary completion
2021-09-01
Completion
2022-10-01
First posted
2021-02-21
Last updated
2021-02-21

Source: ClinicalTrials.gov record NCT04763057. Inclusion in this directory is not an endorsement.